Drugs / Luprolide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01487902 | Jul 2010 → Oct 2013 | castration-resistant prostate carcinoma | Asan Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05873192 Background | Jun 2025 → Dec 2026 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Luprolide | “Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)” NCT01487902 ↗ |
| Known as | Lucrin Depot PDS inj | “Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)” NCT01487902 ↗ |
| Route | Subcutaneous | “every 12 weeks SC” NCT01487902 ↗ |